See more : Hero MotoCorp Limited (HEROMOTOCO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Ventyx Biosciences, Inc. (VTYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventyx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RMG Acquisition Corp. III (RMGCU) Income Statement Analysis – Financial Results
- Arbe Robotics Ltd. (ARBE) Income Statement Analysis – Financial Results
- Khonburi Sugar Public Company Limited (KBS.BK) Income Statement Analysis – Financial Results
- Phoenix Life Sciences International Limited (PLSI) Income Statement Analysis – Financial Results
- Maps S.p.A. (MAPS.MI) Income Statement Analysis – Financial Results
Ventyx Biosciences, Inc. (VTYX)
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 941.00K | 470.00K | 30.00K | 0.00 | 0.00 |
| Gross Profit | -941.00K | -470.00K | -30.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
| General & Administrative | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Other Expenses | 0.00 | 41.00K | -5.45M | -1.00K | -1.00K |
| Operating Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Cost & Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest Income | 15.07M | 4.67M | 78.00K | 358.00 | 146.00 |
| Interest Expense | 0.00 | 0.00 | 99.00K | 358.00K | 146.00K |
| Depreciation & Amortization | 158.00K | 470.00K | 30.00K | 7.05M | 4.18M |
| EBITDA | -207.84M | -107.96M | -67.12M | 0.00 | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.03M | 4.71M | -16.60M | -21.12M | -147.00K |
| Income Before Tax | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -470.00K | -5.38M | 358.00K | 146.00K |
| Net Income | -192.96M | -107.96M | -78.37M | -28.53M | -4.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| EPS Diluted | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| Weighted Avg Shares Out | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
| Weighted Avg Shares Out (Dil) | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX INVESTOR ALERT: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by...
VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
VENTYX STOCK DROP ALERT: Ventyx (Nasdaq:VTYX) Directors Being Investigated for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact BFA Law About Your Rights
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
BREAKING VENTYX ALERT: Ventyx (Nasdaq: VTYX) Stock Declines 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
Source: https://incomestatements.info
Category: Stock Reports